BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

Dezima CETP inhibitor meets endpoint in dyslipidemia trial

Dezima Pharma B.V. (Naarden, the Netherlands) said TA-8995 (DEZ-001) alone or in combination with statin therapy met the primary endpoint vs. placebo in the 364-patient Phase IIb TULIP trial to treat dyslipidemia. The primary endpoint was a composite of the change from baseline in LDL-C and HDL-C at week 12. more >>

   CLINICAL NEWS

ZMapp reverses advanced Ebola in monkeys

In a primate study, ZMapp from Mapp Biopharmaceutical Inc. (San Diego, Calif.) reversed 100% of advanced Ebola cases. A research group led by Gary Kobinger of the University of Manitoba that included Mapp CEO Larry Zeitlin published a paper in Nature showing all 18 rhesus monkeys survived when treated with ZMapp up to five days post infection, with severe symptoms reversed. more >>

   COMPANY NEWS

UTHR soars on patent win

United Therapeutics Corp. (NASDAQ:UTHR) gained $26.14 (29%) to $117.83 on Friday after the U.S. District Court for the District of New Jersey ruled that Sandoz's ANDA for generic intravenous treprostinil will infringe United Therapeutics' U.S. Patent No. 6,765,117. more >>

   FINANCIAL NEWS

Titan proposes to raise up to $12 million

Titan Pharmaceuticals Inc. (OTCBB:TTNP) proposed to raise up to $12 million through the sale of units in a follow-on underwritten by Roth Capital Partners. Each unit comprises a share and a warrant to purchase a share. more >>

Orexo raises $50.6 million

Orexo AB (SSE:ORX; OTCQX:ORXOY) raised SEK346.5 million ($50.6 million) through the sale of 2.5 million shares at SEK139 in a private placement. The company sold 1.1 million treasury shares and issued 1.4 million new shares. Danske Bank is the sole lead manager and bookrunner. Orexo's Zubsolv buprenorphine/naloxone, a sublingual tablet formulation of buprenorphine and naloxone, is marketed in the U.S. to treat opioid dependence. more >>

   POLITICS & POLICY

White House calls for labs to check inventories

In a memorandum, the White House said all federally funded labs working with infectious agents must take "immediate and longer-term steps" to enhance biosafety and biosecurity, including taking an inventory of infectious samples and reviewing safety and security protocols. The memo was sent to federal agencies earlier this month but made publicly available on Thursday. more >>

HOLIDAY NOTICE

BioCentury Extra will not publish on Monday, Sept. 1, in observance of the Labor Day holiday in the U.S. Postings of BioCentury Extra will resume on Tuesday, Sept. 2. more >>

Advertisement

SCIBX: SCIENCE-BUSINESS EXCHANGE

SCIBX: SCIENCE-BUSINESS EXCHANGE
COVER STORY

Overcoming ibrutinib resistance

The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.

TARGETS & MECHANISMS

A cultured approach to ALS therapy

The mechanisms by which dysfunctional glial cells contribute to ALS have remained poorly defined. Now, Harvard University researchers have identified a therapeutic target-prostaglandin D2 receptor subtype DP1-and shown that reducing its expression can prolong survival in a mouse model of ALS.

TRANSLATIONAL NOTES

Getting researchers off the grant treadmill

The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier riches for the top labs but instead makes a difference for up-and-coming researchers.

Industrial strength for Sanford-Burnham

GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.

THERAPEUTICS

This Week in Therapeutics

Treating cardiac hypertrophy with MST2 inhibitors; improving the outcome of HSC transplants with RET agonists; preventing allergic asthma with Helicobacter pylori ggt and vacA; and more...

TECHNIQUES

This Week in Techniques

An Sigirr-deficient mouse model of Campylobacter jejuni infection; a CAR-specific invariant NK T cell therapy; integrated analysis of cancer cells to prioritize the study of cancer drivers; and more...

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement